CrownBio’s metabolic disease portfolio is a unique continuum of translational platforms that enable our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our clients engage with these translational platforms, which include rodent and non-human primates, (NHP) to model human liver disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.
HCD Economics is a technical economics consultancy providing analytic and strategic support to the pharmaceutical and medical device industry. Our unique relationship with the University of Chester, alongside our work with payers and decision-makers, enables us to generate meaningful evidence with academic credibility that resonates with all key stakeholders. Partnering with patient charity organizations ensures the analyses we undertake… Read more
Synexus is the world’s largest site network, with 200 sites and 1,500+ employees. We provide customers with access to more than 100 million patients in key clinical development markets including the United States, Europe, Africa and Asia. Synexus has unmatched capacity to find the right patient for the right trial at the right time. Our global scale and world-class site network delivers unparalleled capability, data-driven site selection and activation, proven patient engagement and retention expertise.